RAISING FUNDS FOR TGEN RESEARCH

Late-stage diagnosis of ovarian cancer and the resulting drug resistance of such advanced tumors has left the success rate of treatment unchanged in the past 30 years, despite improvements in drug therapies.

Dr. Heather Cunliffe, head of the Breast and Ovarian Cancer Research Unit at TGen, endeavors to improve that success rate by understanding why ovarian cancer becomes resistant to therapies while simultaneously developing better drug treatments to address the cancer’s early-stage drug resistance.

Funds raised by the Anne Rita Monahan Foundation (ARM) will provide Dr. Cunliffe, and her team, the financial support needed to fully realize her study and ultimately save lives through early detection methods and improved drug therapies.

MAKE A DONATION AND HELP FIGHT BACK AGAINST OVARIAN CANCER.

The Anne Rita Monahan Foundation is a 501(c)(3) tax-exempt charitable organization under IRS code. Our Federal Tax ID number is 11-3821047.

Click here to donate.